RAPP
Rapport
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RAPP
Rapport Therapeutics, Inc.
A biopharmaceutical company focused on developing small molecule drugs for precise treatment of neurological diseases
1325 Boylston Street, Suite 401 Boston, MA 02215
--
Rapport Therapeutics, Inc., was incorporated under the laws of Delaware in February 2022 as Precision Neuroscience NewCo, Inc., and changed its name to Rapport Therapeutics, Inc. in October 2022. The Company is a clinical-stage biopharmaceutical company focused on becoming a leader in precision neuroscience through the discovery and development of translational small molecule drugs for patients with central nervous system (" CNS ") diseases.
Company Financials
EPS
RAPP has released its 2024 Q4 earnings. EPS was reported at -0.57, versus the expected -0.70, beating expectations. The chart below visualizes how RAPP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
